Parliament Workbench
Data: Motions & questions to 26 Nov 2026

Written Question · S2W-31920 · Session 2

When it expects a decision to be made on the approval of Lucentis for the treatment of age-related macular degeneration.

Answered Asked by Alasdair Morgan SNP Lodged 21 Feb 2007

The question

To ask the Scottish Executive when it expects a decision to be made on the approval of Lucentis for the treatment of age-related macular degeneration.

The answer

Answered by Andy Kerr on 27 Feb 2007 · 6 days after it was lodged, on time

Lucentis® (ranibizumab) was approvedon 22 January 2007 by the European Medicines Evaluation Agency (EMEA). the Scottish Medicines Consortium have this therapy on their work programme and a recommendationis anticipated from them in the next few months.

In the Official Report

No contribution in the Official Report cites S2W-31920 by reference.